TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00035347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV azithromycin
Description: 500 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 1 gram once daily for 2 to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azithromycin
Description: 2 x 250 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV levofloxacin
Description: 500 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral levofloxacin
Description: 500 mg once daily
Study: NCT02919384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% oxygen concentration in the incubator
Description: At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6.
Study: NCT03687164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Medical Visits
Description: Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
Study: NCT04284150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine; Midazolam;
Description: Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
Study: NCT02831907

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: All cardiac surgery procedures with the use of cardiopulmonary bypass
Study: NCT02005198

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionnaire when entering the non-interventional study
Study: NCT04786509

Intervention type: DIAGNOSTIC_TEST
Intervention: Field tests
Description: In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
Study: NCT00971620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Given as an intralesional injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given as an intralesional injection
Study: NCT01376557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg LX4211
Description: Subjects will receive 75 mg LX4211 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg LX4211
Description: Subjects will receive 200 mg LX4211 once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX4211
Description: Subjects will receive 400 mg LX4211 once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg LX4211
Description: Subjects will receive 200 mg LX4211 twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once daily.
Study: NCT02312687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KRN23
Description: solution for SC injection
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV 100 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV 100 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV 100 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV 100 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV 100 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV 440 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV 440 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV 440 mg/m2/dose on Days 1-5
Study: NCT00445445

Intervention type: OTHER
Intervention: screening questionnaire administration
Description: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.

Intervention type: PROCEDURE
Intervention: breast imaging study
Description: Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.

Intervention type: PROCEDURE
Intervention: breast imaging study
Description: Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV 440 mg/m2/dose on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV 440 mg/m2/dose on Days 1-5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC 5 micrograms/kg/dose Only on Day 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC 5 micrograms/kg/dose Only on Day 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC 5 micrograms/kg/dose Only on Day 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC 5 micrograms/kg/dose Only on Day 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC 5 micrograms/kg/dose Only on Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses
Study: NCT00445445

Intervention type: PROCEDURE
Intervention: radiomammography
Description: Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.

Intervention type: PROCEDURE
Intervention: radiomammography
Description: Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.

Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: * Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.

Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: * Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
Study: NCT04048317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaSphere Microspheres/Doxorubicin Hydrochloride
Description: evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipiodol
Description: evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration
Study: NCT04508790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses
Study: NCT04508790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MTX
Description: IV 5000 mg/m2/dose Block 2: Day 22
Study: NCT03426722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: * L-carnitine VS Placebo is randomized (1:1)~* L-carnitine 500mg TID(PO),~* First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500mg TID(PO)
Study: NCT03876769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells
Study: NCT01051765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin
Description: irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
Study: NCT00202722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Intravenous patient controlled analgesia (ivpca) during labour
Study: NCT04518631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness program
Description: The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
Study: NCT05281341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: In GH groups (Group 4A \& 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B \& 3B) will receive only standard COS without GH supplementation
Study: NCT03616730

Intervention type: DIAGNOSTIC_TEST
Intervention: NICOM (non-invasive cardiac output monitor)
Description: Transthoracic bio-reactance, or the non-invasive cardiac output measurement \[NICOMTM, Cheetah Medical Inc., Portland, OR\] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MTX
Description: IV 5000 mg/m2/dose Block 2: Day 22
Study: NCT02217293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency
Description: Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
Study: NCT01263353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR followed by Pasireotide LAR + Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR followed by Pasireotide LAR + Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR followed by Pasireotide LAR + Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR followed by Pasireotide LAR + Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus followed by Pasireotide LAR + Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus followed by Pasireotide LAR + Everolimus
Study: NCT00671320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
Study: NCT03714685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: Firibastat (QGC001) 500 mg
Study: NCT01939756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravesical baobab oil
Description: Intravesical baobab oil
Study: NCT03892408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow ™
Description: supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MTX
Description: IV 5000 mg/m2/dose Block 2: Day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MTX
Description: IV 5000 mg/m2/dose Block 2: Day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose MTX
Description: IV 5000 mg/m2/dose Block 2: Day 22
Study: NCT04406337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound
Description: Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm\^2 (0.03 W/cm\^2 ) and 20% duty cycle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity continuous ultrasound
Description: High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm\^2 and 100% duty cycle.
Study: NCT02145793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Group Curriculum
Description: Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
Study: NCT03522987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
Study: NCT01620736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg po bid
Study: NCT03619174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viveve Treatment
Description: The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Viveve Treatment
Description: The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
Study: NCT00743093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
Study: NCT02595177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with intraocular lens implantation.
Description: Phacoemulsification under topical anesthesia with intraocular lens implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with intraocular lens implantation.
Description: Phacoemulsification under topical anesthesia with intraocular lens implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with intraocular lens implantation.
Description: Phacoemulsification under topical anesthesia with intraocular lens implantation.
Study: NCT00801424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humidified warmed CO2
Description: Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher\&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
Study: NCT00793832

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supervised exercise
Description: supervised exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet advice
Description: Diet Advice
Study: NCT00447577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate and tobramycin ophthalmic suspension
Description: Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin and dexamethasone ophthalmic suspension
Description: Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
Study: NCT04266405

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle (50 mL) per day for 28 days
Study: NCT04431687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD 501
Description: QD, PO
Study: NCT04266405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Cubilose Drink
Description: consume 1 bottle (50 mL) per day for 28 days
Study: NCT02303405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Anti-inflammatory and anti-malarial agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Anti-hyperglycemic agent